AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01923506 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT01923506 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00851357 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Patch
Description: Subjects are randomized into 1 of 3 conditions: active, placebo or usual care. Usual care subjects are not mailed patches; however, we facilitate their use by providing a certificate that can be used by the State Medicaid program and some insurance companies to obtain free patches. For those mailed patches directly, we will mail 8 weeks of patches. Dosage depends on the number of cigarettes per day (cpd). Light smokers (6-10 cpd) will receive 6 weeks of 14 mg and 2 weeks of 7 mg patches. Heavy smokers (11+ cpd) will receive 4 weeks of 21 mg, 2 weeks of 14 mg and 2 weeks of 7 mg patches. Placebo patches will have no nicotine, but will be packaged to mimic the active patches.
Study NCT00851357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch
Description: Subjects are randomized into 1 of 3 conditions: active, placebo or usual care. Usual care subjects are not mailed patches; however, we facilitate their use by providing a certificate that can be used by the State Medicaid program and some insurance companies to obtain free patches. For those mailed patches directly, we will mail 8 weeks of patches. Dosage depends on the number of cigarettes per day (cpd). Light smokers (6-10 cpd) will receive 6 weeks of 14 mg and 2 weeks of 7 mg patches. Heavy smokers (11+ cpd) will receive 4 weeks of 21 mg, 2 weeks of 14 mg and 2 weeks of 7 mg patches. Placebo patches will have no nicotine, but will be packaged to mimic the active patches.
Study NCT00851357 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Counseling
Description: Subjects call the Helpline and are screened for services. Eligible clients who give consent will be randomly assigned to a group.~Subjects will be randomized into one of 2 behavioral conditions: telephone counseling or self-help materials. Telephone counseling includes a comprehensive pre-quit session (to include motivation, planning, and setting of a quit date and discussion of nicotine patch use) plus up to 5 proactive follow-up calls. Telephone counseling has several distinguishing features, namely proactive follow up counseling calls, a manualized protocol, and relapse-sensitive scheduling.
Study NCT00851357 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Telephone Counseling
Description: Subjects call the Helpline and are screened for services. Eligible clients who give consent will be randomly assigned to a group.~Subjects will be randomized into one of 2 behavioral conditions: telephone counseling or self-help materials. Telephone counseling includes a comprehensive pre-quit session (to include motivation, planning, and setting of a quit date and discussion of nicotine patch use) plus up to 5 proactive follow-up calls. Telephone counseling has several distinguishing features, namely proactive follow up counseling calls, a manualized protocol, and relapse-sensitive scheduling.
Study NCT00851357 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone Counseling
Description: Subjects call the Helpline and are screened for services. Eligible clients who give consent will be randomly assigned to a group.~Subjects will be randomized into one of 2 behavioral conditions: telephone counseling or self-help materials. Telephone counseling includes a comprehensive pre-quit session (to include motivation, planning, and setting of a quit date and discussion of nicotine patch use) plus up to 5 proactive follow-up calls. Telephone counseling has several distinguishing features, namely proactive follow up counseling calls, a manualized protocol, and relapse-sensitive scheduling.
Study NCT00851357 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo nicotine patch
Study NCT02373943 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: β-carotene supplemented maize
Description: Determination of all-trans retinol AUC values after the ingestion of 200 g porridge made with 50 g of flour of β-carotene supplemented maize
Study NCT00851357 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo nicotine patch
Study NCT00851357 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-Help Materials
Description: Subjects call the Helpline and are screened for services. Eligible clients who give consent will be randomly assigned to a group.~Subjects will be randomized into one of 2 behavioral conditions: telephone counseling or self-help materials. Reading materials and written consent will be mailed to all study subjects the next business day.
Study NCT02373943 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Normal (non biofortified) maize without added β-carotene
Description: Determination of all-trans retinol AUC values after the ingestion of 200 g porridge made with 50 g of flour of normal maize
Study NCT01805401 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Anode placed over the OFC or the DLPFC and cathode placed over the occipital region
Study NCT01805401 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: Anode placed over the OFC or the DLPFC and cathode placed over the occipital region
Study NCT02585232 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling (C)
Description: The counseling component incorporates elements of existing manualized interventions that have been tailored for this population and follow a cognitive behavioral therapy framework. Counseling sessions will be completed for 8-10 domains of potential distress (grief, hostility, sexual intimacy, etc.).
Study NCT02585232 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Care Consultation (CC)
Description: Care Consultation (CC): is an established telephone-based, empowerment intervention that uses coaching and emotional support to mobilize family caregivers and individuals with dementia through psychoeducation, resource referral, psychosocial support, and encouragement of informal and formal service use utilization. A computerized clinical tool called the Care Consultation Information System (CCIS) guides the care consultant through a standardized delivery of protocol components. Rather than a strong focus on assessment, this intervention is designed to quickly identify areas of unmet need through brief trigger questions called the initial assessment, which then immediately shapes development of concrete action plans.
Study NCT02585232 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care Consultation (CC)
Description: Care Consultation (CC): is an established telephone-based, empowerment intervention that uses coaching and emotional support to mobilize family caregivers and individuals with dementia through psychoeducation, resource referral, psychosocial support, and encouragement of informal and formal service use utilization. A computerized clinical tool called the Care Consultation Information System (CCIS) guides the care consultant through a standardized delivery of protocol components. Rather than a strong focus on assessment, this intervention is designed to quickly identify areas of unmet need through brief trigger questions called the initial assessment, which then immediately shapes development of concrete action plans.
Study NCT03912246 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: biological samples
Description: collection of blood, urine, saliva, stool, skin and mouth swabs, tears
Study NCT03912246 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lumbar puncture
Description: collection of cerebrospinal fluid
Study NCT02443974 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brace (Fisiotensor®)
Study NCT02443974 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sleeve (Fisiotensor®)
Study NCT00942565 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tramadol/acetaminophen
Study NCT00942565 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetaminophen
Study NCT02472860 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted Cognitive Training (TCT)
Description: The investigators have selected a set of computer exercises designed to specifically target aspects of cognition relevant to autism spectrum disorder (including attention and executive functions). The tasks were designed to benefit subjects through principles of learning dependent plasticity.
Study NCT02472860 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Youth Appropriate Online Games
Description: Engaging games not designed to improve cognition
Study NCT04803266 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Internal mammary node irradiation
Description: Regional nodal irradiation including internal mammary node irradiation along with breast or chest wall irradiation after breast-cancer surgery
Study NCT04803266 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: No internal mammary node irradiation
Description: Regional nodal irradiation not including internal mammary node irradiation along with breast or chest wall irradiation after breast-cancer surgery
Study NCT02313259 — intervention group
Intervention type: OTHER
Intervention: Speed discrimination test
Description: The participant has to stare in the middle of two screens, i.e the reference screen and the test screen. Dots are moving from the center to the edge of the screens at different speeds. The participant is forced to determine if the dots of the test screen are moving faster or slower than the reference screen.~The test is designed in Psychtoolbox3. Data analyses performed using MATLAB. Two-alternative forced choice paradigm.
Study NCT02313259 — intervention group
Intervention type: BEHAVIORAL
Intervention: Driving simulation
Description: 25 km simulated car driving session. The participant is seated in the driver compartment of a real car featuring all the actual components (steering wheel, pedals regulating speed and brakes). He is instructed to respect road regulations as well as safety rules and must perform some driving manoeuvres, such has turning at intersections, stopping when necessary, passing another car, etc.~Software Drive 3.0 by Systems Technology Inc., Hawthorne, California, USA. Magnetic head tracker (Flock of Birds, Ascension Technology Corporation, Burlington, Vermont, USA).~A fixed-base driving simulator. 2 driving scenarios: a practice (10 minutes) and a main scenario including rural and urban sections (35 minutes).
Study NCT03038321 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sofenacin
Description: solifenacin 10 mg, 6 hours after IVI of BCG and continue for another 2 days post instillation
Study NCT03038321 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tavanic
Description: levofloxacin 500 mg, 6 hours after IVI of BCG and continue for another 2 days post instillation.
Study NCT03038321 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xefo
Description: lornoxicam 8 mg, 6 hours after IVI of BCG and continue for another 2 days post instillation.
Study NCT00637065 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bosentan
Description: Bosentan tablets - 62.5mg bd for first 4 weeks, then 125mg bd if tolerated until trial completion.
Study NCT00637065 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tables - identical to active drug but without the active ingredient -
Study NCT06514872 — intervention group
Intervention type: OTHER
Intervention: prevalance and determinants of home accidents
Description: home accidents among Turkish older
Study NCT01239069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-110 ophthalmic suspension high dose
Description: ophthalmic suspension; high dose; QID
Study NCT01239069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-110 ophthalmic suspension low dose
Description: ophthalmic suspension; low dose; QID
Study NCT01239069 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: DE-110 ophthalmic suspension vehicle;QID
Study NCT02329470 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Withdrawal of continuous positive airway pressure treatment
Description: Withdrawal of continuous positive airway pressure treatment
Study NCT00472225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab Induction: Rituximab 375 mg/m2 weekly IV for 4 consecutive weeks~Rituximab Maintenance: Rituximab 375 mg/m2 monthly IV for 4 consecutive months
Study NCT03976765 — intervention group
Intervention type: OTHER
Intervention: Rehabilitation program
Description: The patients follow different rehabilitation programs (surgery, anesthetic, post-operative). Hospital discharge is authorized only after validation of objective, clinical and para clinic criteria
Study NCT01178463 — intervention group
Intervention type: OTHER
Intervention: Biospecimen staining
Description: The sections will be incubated with rabbit anti GPR125 followed by Cy3-conjugated anti rabbit secondary antibodies.
Study NCT00670215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin single dose
Description: Patients randomized to this regimen will receive a single-dose of ciprofloxacin MR 1000 mg PO approximately 2 to 3 hours prior to the TRNBP. Patients will also receive two doses of matching placebo approximately 24 hours prior to and approximately 24 hours after the TRNBP.
Study NCT00670215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin triple dose
Description: Patients randomized to this regimen will receive three doses of ciprofloxacin MR 1000 mg PO. The doses will be approximately 24 hours prior to the TRNBP, approximately 2 to 3 hours prior to the TRNBP, and approximately 24 hours after the TRNBP.
Study NCT00866463 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: Single Dose of 50 mg Sildenafil Oral Tablet With Water
Study NCT00866463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Single Dose of 50 mg Sildenafil Experimental Tablet With Water
Study NCT00866463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Single Dose of 50 mg Sildenafil Experimental Tablet Without Water
Study NCT04623788 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac MRI
Description: Cardiac MRI with contrast
Study NCT01292941 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent catheterisation
Description: Speedicath, Intermittent catheterisation
Study NCT01292941 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NonCE marked intermittent catheter/red
Description: Paris, Intermittent catheterisation
Study NCT01292941 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NonCE marked intermittent catheter/green
Description: Paris, Intermittent catheter
Study NCT01292941 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NonCE marked intermittent catheter/blue
Description: Paris, Intermittent catheter
Study NCT00404651 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-HB-PRP~T vaccine
Description: 0.5 mL, intramuscular (IM)
Study NCT00404651 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-HB-PRP~T vaccine
Description: 0.5 mL, IM
Study NCT00404651 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTaP-HBV-IPV vaccine
Description: 0.5 mL, IM
Study NCT04052490 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Abutment with flat occlusal reduction with feather edge finish
Description: Non vital teeth require a full coverage restoration to withstand the functional stresses and prevent any further destruction of tooth/crown complex. The zirconia all-ceramic crowns yield a high flexure strength and are used as an esthetic alternative to ceramo-metallic crowns. Several studies linked the effect of preparation designs to the survival of the restoration. Others, studied the effect of the finish line geometries as deep chamfer and shoulder on the marginal integrity of restorations. The feather edge finish line is used with zirconia crowns with limited data regarding its success. However, there is no presented research dealing with the effect of finishing line designs in combination with different occlusal reduction schemes on the marginal fit of full contour zirconia crowns.
Study NCT02028377 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET/MRI
Description: PET/MRI
Study NCT00367328 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 1320nm Nd: YAG nonablative laser
Description: a 4 mm piece of skin tissue (about the size of a pencil-head eraser) from the affected area. This procedure is called a punch biopsy and will be done to confirm your diagnosis. A culture swab similar to a Q-Tip will be used to wipe the affected areas during the first visit to determine any bacteria that may be present. A survey with questions will be given at the first visit, again after 3 months and at the last visit to measure the success of the treatment. Photographs will be taken prior to each treatment and one month following your last treatment. A laser, which is a very powerful light, will be used to treat half of the skin that is affected by your condition.
Study NCT02539771 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Polysomnography and blood sample
Description: Blood collection is a specific intervention of protocol for the 3 arms. Polysomnography is a specific intervention for the arms  Diurnal VOC  and  Slightly symptomatic
Study NCT01383746 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Yttrium microsphere injection
Description: Radiation therapy
Study NCT04356495 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Vitamins
Description: 2 tablets daily from the first day (day 0) to day 9
Study NCT04356495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan
Description: 1 tablet daily from the first day (day 0) to day 9
Study NCT04356495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclesonide
Description: 2 puffs twice a day in an inhalation chamber from the first day (day 0) to day 9
Study NCT04356495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: interferon β-1b
Description: A 10-minute nebulization, once a day, from the first day (day 0) to day 4, of 9.6 MIU / 300 µg of IFN-β-1b (EXTAVIA®) diluted in 2 mL of water
Study NCT01755364 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdimFlu-V
Study NCT00350025 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cetuximab
Description: Cetuximab 250mg/m2 IV weekly for each 28 day cycle.
Study NCT00350025 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Paclitaxel
Description: Paclitaxel 80mg/m2 IV weekly for each 28 day cycle.
Study NCT03707795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betamethasone sodium phosphate/betamethasone acetate (Celestone® Soluspan®), 30 mg IM once a day for four days
Description: Participants will be given four IM injections throughout the study
Study NCT03707795 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone sodium phosphate/betamethasone acetate (Celestone® Soluspan®), 30 mg IM once a day for four days
Description: Participants will be given four IM injections throughout the study
Study NCT04291612 — intervention group
Intervention type: OTHER
Intervention: Physical exam
Description: Part 2 participants will be prospectively followed clinically for relapse for 30 months from the date of surgery for physical examination at post-ops visits.
Study NCT04243694 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness training
Description: Participants of the intervention group will receive 6-weeks of mindfulness training.
Study NCT01972581 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reaction Time Training
Study NCT03689023 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A controlled multimodal intervention
Description: The intervention is interdisciplinary, multimodal and patient activating and uses the existing setting and work flows at the Clinic as well as new interventions, ensuring that the patients receive education about cardiovascular risk factors, physical activity and healthy diet through a systematic approach including targeted patient education
Study NCT02063204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selumetinib
Description: selumetinib 50 mg (2x25mg) administered by mouth as capsules
Study NCT02211053 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levothyroxine
Description: 20 mg IV bolus + 10 mg/h infusion
Study NCT02211053 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT04126694 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT with smartphone application SenseSupport
Description: SenseSupport intervention system used as an augment to a 12 week in-person CBT treatment for transdiagnostic binge eating pathology
Study NCT03263546 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavioral therapy (ICBT)
Description: Participants will receive internet-delivered CBT with therapist support for 16 weeks. The treatment consists of 14 online chapters with interactive features as videos and illustrations. The treatment has the main focus on exposure with ritual prevention. The children and parents have regular contact with a personal assigned therapist via written text messages in the platform.~Participants that are classified as non-responders at 3 months follow-up will receive face-to-face CBT of up to 12 sessions over 12 weeks.